Corbus announces presentation of dose expansion Phase 1/2 data for CRB-701

Corbus Pharmaceuticals (CRBP) Holdings announced that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the United States and Europe of CRB-701 has been accepted for presentation as a poster at the European Society for Medical Oncology Congress 2025, to be held October 17-21, 2025 in Berlin, Germany. The abstract, a Phase 1/2 study of the next-generation Nectin-4-targeting antibody-drug conjugate CRB-701 in patients with urothelial and non-urothelial solid tumours by Perez et al, will be presented as a poster on Sunday, October 19 from 12:00-12:45 CEST. The three-part Phase 1/2 study is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in participants with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses and Part C. Dose optimization is on-going with dosing at 2.7 mg/kg and 3.6 mg/kg cohorts in HNSCC, cervical and mUC tumors. The Company expects to complete dose optimization and identify a recommended Phase 2 dose in the fourth quarter of 2025.